KALV
KalVista Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.00
+0.00%Income statement
| Metric | TTM | 2025 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 220.6M | 73.6M | — | — | — |
| Cost of Revenue | 19.0M | 6.1M | — | 86.2M | — |
| Gross Profit | 201.7M | 67.5M | — | (86.2M) | — |
| Operating Expenses | |||||
| R&D Expense | 39.0M | 55.6M | 71.7M | 86.2M | 80.3M |
| SG&A Expense | 229.0M | 183.7M | 116.3M | 54.3M | 30.6M |
| General & Admin Expense | — | — | 116.3M | 54.3M | 30.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (4.8M) | — | — | (86.2M) | — |
| Total Operating Expenses | 263.2M | 239.4M | 188.0M | 54.3M | 110.9M |
| Cost and Expenses | 282.2M | 245.5M | 188.0M | 140.4M | 110.9M |
| Operating Income (EBIT) | (61.6M) | (171.8M) | (188.0M) | (140.4M) | (110.9M) |
| Non-Operating | |||||
| Interest Income | 12.7M | 8.7M | 6.4M | 3.9M | 2.2M |
| Interest Expense | 31.5M | 19.3M | 5.8M | — | — |
| Net Interest Income | (18.9M) | (10.7M) | 650.0K | 3.9M | 2.2M |
| Other Non-Op Income/Expense | 678.0K | 420.0K | 7.9M | 5.3M | 18.0M |
| Non-Operating Income (excl Interest) | (13.2M) | (19.8M) | (13.7M) | (5.3M) | (15.8M) |
| EBT (Pre-Tax Income) | (60.9M) | (171.4M) | (180.1M) | (135.1M) | (92.9M) |
| Income Tax Expense | (21.3M) | (7.1M) | 3.4M | (8.5M) | — |
| Bottom Line | |||||
| Net Income | (39.6M) | (164.3M) | (183.4M) | (126.6M) | (92.9M) |
| Earnings from Cont. Ops | (39.6M) | (164.3M) | (183.4M) | (126.6M) | (92.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (39.6M) | (164.3M) | (183.4M) | (126.6M) | (92.9M) |
| Per Share | |||||
| Basic EPS | ($1.41) | ($3.23) | ($3.69) | ($3.44) | ($3.33) |
| Diluted EPS | ($1.41) | ($3.23) | ($3.69) | ($3.44) | ($3.33) |
| Revenue Per Share | $4.37 | $1.45 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 50.5M | 50.9M | 49.7M | 36.8M | 27.9M |
| Diluted Shares Outstanding | 50.5M | 50.9M | 49.7M | 36.8M | 27.9M |
| Profitability Metrics | |||||
| EBITDA | (46.2M) | (150.6M) | (173.3M) | (134.3M) | (94.4M) |
| D&A | 2.1M | 1.5M | 941.0K | 816.0K | 718.0K |
| EBIT | (48.3M) | (152.1M) | (174.3M) | (135.1M) | (95.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026